• PIN57 UPTAKE OF PRE-EXPOSURE PROPHYLAXIS (PREP) AND TYPE OF PROVIDERS AMONG COMMERCIALLY-INSURED PERSONS IN THE UNITED STATES, 2012-2018

    May 1, 2020, 00:00

  • PDB35 A COST MINIMIZATION ANALYSIS OF NEGATIVE PRESSURE WOUND THERAPY TECHNOLOGIES FOR THE TREATMENT OF MODERATE TO SEVERE FOOT INFECTIONS

    May 1, 2020, 00:00

  • PDB69 FACTORS ASSOCIATED WITH PRE-DIABETES IN THE U.S ‘DIABETES-BELT’ REGION POPULATION

    May 1, 2020, 00:00

  • PBI17 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

    May 1, 2020, 00:00

  • PIH10 COST-EFFECTIVENESS ANALYSIS OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN OSTEOARTHRITIS IN CHINA

    May 1, 2020, 00:00

  • PBI42 DISCONTINUATION PLAYS A ROLE WHEN EVALUATING THE COST EFFECTIVENESS OF THE SECOND BIOLOGICAL DRUG FOR PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2020, 00:00

  • PMU20 A DEVICE CATEGORY-BASED ECONOMIC MODEL EXPLORING ELECTROSURGERY TECHNOLOGIES ACROSS PROCEDURE TYPES: A UNITED STATES ANALYSIS

    May 1, 2020, 00:00

  • PMU30 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING FOR SPINAL MUSCULAR ATROPHY (SMA) IN THE UNITED STATES

    May 1, 2020, 00:00

  • Alternative Medicine Nutrition - Economic Evaluation

    May 1, 2020, 00:00

  • PIN79 VACCINATION COVERAGE RATE: WHAT CAN WE EXPECT FROM BRAZIL?

    May 1, 2020, 00:00

  • Advanced Analytics Studies

    May 1, 2020, 00:00

  • PDB99 BASELINE CHARACTERISTICS OF ENDOMETRIOSIS PATIENTS PARTICIPATING IN A REAL WORLD PROSPECTIVE COHORT STUDY: AN INTERIM ANALYSIS OF THE ELAGOLIX LONGITUDINAL OUTCOMES (LOTUS) STUDY

    May 1, 2020, 00:00

  • PDG56 APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN CHINA NATIONAL REIMBURSEMENT DRUG LIST PRICE NEGOTIATIONS: THE EVOLVING TREND AND IMPLICATIONS

    May 1, 2020, 00:00

  • PMD26 A COST-EFFECTIVENESS AND SENSITIVITY ANALYSIS OF METAL NEEDLES COMPARED WITH PLASTIC FISTULA CANNULAS FOR HEMODIALYSIS PATIENTS IN MEXICO, CONSIDERING NEEDLE-INDUCED INJURY REQUIRING INTERVENTION

    May 1, 2020, 00:00

  • PDB93 NAFLD SIMULATOR: A WEB-BASED SIMULATION TOOL TO PREDICT LONG-TERM OUTCOMES OF NON-ALCOHOLIC FATTY LIVER DISEASE

    May 1, 2020, 00:00

  • PBI10 BUDGET IMPACT ANALYSIS OF MEPOLIZUMAB AS AN ADD-ON THERAPY IN THE TREATMENT OF SEVERE EOSINOPHILIC ASTHMA IN CHILE

    May 1, 2020, 00:00

  • PCV56 COMPARISON OF THE FRAMINGHAM, PROCAM AND MODIFIED FRAMINGHAM RISK SCORES FOR PREDICTING CARDIOVASCULAR EVENTS IN A COHORT FROM A CARDIOVASCULAR PREVENTION PROGRAM IN THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PDB34 THE DIABETES PREVENTION PROGRAM (DPP) QUALITY OF WELL BEING (QWB) UTILITY MEASURES AND MISSING DATA CONSIDERATIONS: AVAILABLE CASE ANALYSIS (ACA) VS. MULTIPLE IMPUTATION (MI) RESULTS FOR UTILITIES AND QUALITY ADJUSTED LIFE YEARS (QALY ...

    May 1, 2020, 00:00

  • PCV68 PREDICTORS OF FAILURE-TO-RESCUE FOR ACUTE MYOCARDIAL INFARCTION

    May 1, 2020, 00:00

  • PMH24 BUDGET IMPACT ANALYSIS OF VORTIOXETINE AND/OR SERTRALINE USE FOR MANAGEMENT OF MAJOR DEPRESSIVE DISORDER IN THE KINGDOM OF SAUDI ARABIA

    May 1, 2020, 00:00

  • PMS25 CLINICAL VALIDATION OF A BUDGET IMPACT MODEL USING THE ESTABLISHED KEY OPINION LEADER VALIDATION FRAMEWORK (KOLVF)

    May 1, 2020, 00:00

  • PIN60 VISUALIZING THE IMMUNIZATION RATES IN NIGERIA: MAPPING THE CRISIS TO TARGET RESOURCES ALLOCATION

    May 1, 2020, 00:00

  • PDG3 EVALUATION OF PROGESTERONE (17-ALPHA HYDROXYPROGESTERONE CAPROATE (17-OHPC)) UTILIZATION, ADHERENCE, AND OUTCOMES IN WOMEN WITH A HIGH-RISK PREGNANCY

    May 1, 2020, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Economic Evaluation

    May 1, 2020, 00:00

  • PDG15 ECONOMIC ASSESSMENT OF SWITCHING FROM DIPEPTIDYL PEPTIDASE-4 INHIBITORS TO SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS OR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USING REAL-WORLD DATA

    May 1, 2020, 00:00

  • Infectious Diseases - Economic Evaluation

    May 1, 2020, 00:00

  • PMH35 MENTAL AND BEHAVIORAL DISORDERS DUE TO OPIOID USE IN COLOMBIA: PREVALENCE AND DEMOGRAPHIC CHARACTERISTICS 2009-2018

    May 1, 2020, 00:00

  • PIN51 FACTORS ASSOCIATED WITH INCREASED RISK OF HERPES ZOSTER AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Medical Technologies

    May 1, 2020, 00:00

  • PMS29 EARLY ECONOMIC EVALUATION DEMONSTRATES THAT ROBOTIC ASSISTED SURGERY IS COST-EFFECTIVE IN PATIENTS UNDERGOING UNICOMPARTMENTAL KNEE ARTHROPLASTY, A UK NATIONAL HEALTH SERVICE PERSPECTIVE

    May 1, 2020, 00:00

  • PIH4 NUMBER NEEDED TO TREAT (NNT) WITH FENFLURAMINE TO ACHIEVE A CLINICALLY MEANINGFUL REDUCTION IN CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME: HEALTH ECONOMIC IMPLICATIONS

    May 1, 2020, 00:00

  • PDB14 HYPOTHERMICALLY STORED HUMAN AMNIOTIC MEMBRANE (HSAM) FOR THE MANAGEMENT OF DIABETIC FOOT ULCERS

    May 1, 2020, 00:00

  • PDB44 DOES INCLUDING ACUTE PANCREATITIS AS A COMPLICATION HAVE AN IMPACT ON COST-EFFECTIVENESS ANALYSES USING THE IQVIA CORE DIABETES MODEL?

    May 1, 2020, 00:00

  • PCV58 DEFINING THROMBOEMBOLIC EVENTS USING ADMINISTRATIVE CLAIMS DATA

    May 1, 2020, 00:00

  • PIH20 OUTCOME AND ECONOMIC EVALUATION OF NEONATAL SCREENING USING MS/MS FOR INHERITED METABOLIC DISEASES

    May 1, 2020, 00:00

  • PIN5 PREVALENCE OF DRUG RESISTANCE IN NUCLEOSIDE/NUCLEOTIDE ANALOGUE-TREATED EGYPTIAN PATIENTS WITH CHRONIC HEPATITIS B VIRUS

    May 1, 2020, 00:00

  • Medical Devices - Methodological Statistical Research

    May 1, 2020, 00:00

  • PMD48 ROBOTIC TOTAL HYSTERECTOMY: ASSOCIATION OF SURGICAL INDICATION WITH USE OF ROBOTIC-ASSISTANCE AND RELATED HEALTHCARE RESOURCE UTILIZATION AND COSTS

    May 1, 2020, 00:00

  • Infectious Diseases - Epidemiology Public Health

    May 1, 2020, 00:00

  • PDG50 COMMUNICATION BETWEEN PATIENTS AND HEALTH CARE PROFESSIONALS ABOUT OPIOID MEDICATIONS: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • Alternative Medicine Process of Care

    May 1, 2020, 00:00

  • PMH16 DRUG EXPENDITURE, PRICE, AND UTILIZATION IN THE U.S. MEDICAID PROGRAM: AN EMPIRICAL TREND ANALYSIS FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) ANTIDEPRESSANTS FROM 1991 ...

    May 1, 2020, 00:00

  • Multiple Diseases - Health Policy Regulatory

    May 1, 2020, 00:00

  • PMD24 ANALYSIS OF THE COST-EFFECTIVENESS OF THE LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM AS ALTERNATIVE TO HISTERECTOMIES IN PRIVATE HEALTH INSURANCE IN BRAZIL

    May 1, 2020, 00:00

  • PMU27 ASSESSING RELATIONSHIPS AMONG HOSPITALIZATIONS FOR SPINE-RELATED INFECTIONS, DEMOGRAPHICS, COSTS, AND COMORBIDITY DIAGNOSES IN THE UNITED STATES

    May 1, 2020, 00:00

  • PDG70 OPIOID USE IN CHRONIC NON-CANCER PAIN: ANALYSIS USING MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATABASE

    May 1, 2020, 00:00

  • PDG9 PREVALENCE OF POLYMEDICATION IN POOR POPULATION OF THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PIH45 COST-EFFECTIVENESS OF A CARE PUBLIC PROGRAM FOR PREGNANT WOMEN WHO HAD THEIR DELIVERY IN A THIRD - LEVEL - COMPLEXITY HOSPITAL AT COLOMBIA

    May 1, 2020, 00:00

  • PMS56 EPIDEMIOLOGICAL DISEASE BURDEN OF FRACTURE OF SKULL AND FACIAL BONES BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PMH36 THE RELATIONSHIP BETWEEN IRON DEFICIENCY ANAEMIA AND ANTENATAL DEPRESSION AMONG PREGNANT WOMEN

    May 1, 2020, 00:00

  • PDG17 COST-EFFECTIVENESS ANALYSIS OF ARSENIC TRIOXYDE FOR FIRST LINE TREATMENT OF ACUTE PROMYELOCTIC LEUKEMIA

    May 1, 2020, 00:00

  • PDB9 THE COMPARATIVE EFFICACY OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA)

    May 1, 2020, 00:00

  • PIH25 PRE-TERM LABOR TRANSPORT: UTILIZATION PATTERNS AND COST AMONG WOMEN IN RURAL AND NON-RURAL AREAS

    May 1, 2020, 00:00

  • PIN34 COST-UTILITY ANALYSIS OF DIRECT ACTING ANTIVIRALS FOR EARLY-STAGE GENOTYPE 1 HCV PATIENTS IN BRAZIL

    May 1, 2020, 00:00

  • PIH67 EVALUATING THE BURDEN OF ILLNESS OF PEDIATRIC PLATINUM-INDUCED HEARING LOSS: A SYSTEMATIC LITERATURE REVIEW

    May 1, 2020, 00:00

  • Drugs Regulatory

    May 1, 2020, 00:00

  • PIN72 NON-PRESCRIPTION SALES OF ANTIMICROBIALS FROM COMMUNITY PHARMACIES AND DETERMINANTS OF RESISTANCE IN LAHORE PAKISTAN

    May 1, 2020, 00:00

  • PMS62 EPIDEMIOLOGICAL DISEASE BURDEN OF INJURIES TO THE WRIST AND HAND BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PMU33 THE IMPACT OF HIGH RISK AND CHRONIC OPOID USE AMONG COMMERCIALLY INSURED ENDOMETRIOSIS PATIENTS ON HEALTHCARE RESOURCE USE AND COSTS IN THE UNITED STATES

    May 1, 2020, 00:00

  • PDB104 OPTIMIZATION OF INSULIN DOSE IN HOSPITALIZED PATIENTS WITH RECURRENT HYPOGLYCEMIA: REAL WORLD EXPERIENCE

    May 1, 2020, 00:00

  • PCN16 RESECTION FOR RECURRENT BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00

  • PDB63 MULTIMORBIDTY AND FIVE-YEAR TREND IN DIABETES CARE MANAGEMENT (DCM) AMONG ADULTS WITH DIABETES

    May 1, 2020, 00:00

  • PCV89 ASSESSMENT OF CARE OPPORTUNITY GAPS FOR ATRIAL FIBRILLATION IN NHS ENGLAND

    May 1, 2020, 00:00

  • Mental Health - Health Service Delivery Process of Care

    May 1, 2020, 00:00

  • PDG13 CURRENT PRESCRIPTION PROFILE OF RIBAVIRIN FOR HEPATITIS C IN BRAZIL AND THE BUDGET IMPACT ANALYSIS ON UPDATED RECOMMENDATIONS FOR ITS USE BETWEEN 2020 AND 2024 IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

    May 1, 2020, 00:00

  • PMU50 CHARACTERIZATION AND TRENDS OF MATERNAL MORTALITY IN TWO TERTIARY HOSPITALS IN NIGERIA: WHY DID THEY DIE?

    May 1, 2020, 00:00

  • PDB92 GETTING THE MOST OUT OF LATENT-CLASS ANALYSIS IN MODELING PREFERENCES FOR AN INTERCEPTION TREATMENT IN TYPE 1 DIABETES

    May 1, 2020, 00:00

  • PDB13 ASSOCIATION OF VERAPAMIL THERAPY AND REDUCED HYPOGLYCEMIC EVENTS AMONG MEDICARE PATIENTS WITH NEWLY DIAGNOSED TYPE 1 DIABETES

    May 1, 2020, 00:00

  • Cancer - Clinical Outcomes

    May 1, 2020, 00:00

  • Medical Devices - Epidemiology Public Health

    May 1, 2020, 00:00

  • PIN4 IMPACT OF ADHERENCE ON VIRAL SUPPRESSION IN PATIENTS WITH HIV RECEIVING BICTEGRAVIR OR DOLUTEGRAVIR REGIMENS

    May 1, 2020, 00:00

  • Alternative Medicine Nutrition - Patient-Centered Research

    May 1, 2020, 00:00

  • PIN9 ADHERENCE ISSUES AMONG PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY AND CONCOMITANT NON-ANTIRETROVIRAL COMEDICATIONS: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • PCV84 BASELINE CHARACTERISTICS OF HEARTH FAILURE PATIENTS IN A PRIVATE PROVIDER IN CHILE

    May 1, 2020, 00:00

  • PBI23 DEPRESSION AND OBESITY DIFFERENCES AMONG PSORIASIS PATIENTS BY BIOLOGICS TREATMENT

    May 1, 2020, 00:00

  • Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit–Harm Assessments [Editor's Choice]

    May 1, 2020, 00:00

  • PMH17 ECONOMIC BURDEN OF MEDICAID BENEFICIARIES WITH SCHIZOPHRENIA NOT ADHERENT TO ANTIPSYCHOTICS AND WITH SCHIZOPHRENIA RELAPSES

    May 1, 2020, 00:00

  • PMS21 ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ELBOW AND FOREARM BASED ON ROUTINELY COLLECTED REAL-WORLD FINANCING DATA

    May 1, 2020, 00:00

  • PCV79 GENDER DISPARITY IN THE INITIATION AND COMPLIANCE FOR STATIN THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD)

    May 1, 2020, 00:00

  • PMS57 EPIDEMIOLOGIC MODELING TO GUIDE PAYER DECISIONS IN RARE DISEASES: A CASE STUDY OF DUCHENNE MUSCULAR DYSTROPHY IN THE UNITED STATES

    May 1, 2020, 00:00

  • PMD46 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM BEARING SURFACE AND MORTALITY IN HIP AND KNEE REPLACEMENT 180-DAY EPISODE CLAIMS

    May 1, 2020, 00:00

  • PMH31 RISK OF FALLS AND FRACTURES ASSOCIATED WITH CONCOMITANT USE OF ACETYLCHOLINESTERASE INHIBITORS AND ATYPICAL ANTIPSYCHOTICS AMONG OLDER ADULTS WITH DEMENTIA

    May 1, 2020, 00:00

  • PB3 DISCORDANCE BETWEEN PSYCHIATRISTS AND THEIR PATIENTS ON DISEASE SEVERITY AND TREATMENT OUTCOMES IN SCHIZOPHRENIA

    May 1, 2020, 00:00

  • PIN56 VACCINE EXPOSURE DURING PREGNANCY AMONG PRIVATELY AND PUBLICLY INSURED WOMEN IN THE UNITED STATES

    May 1, 2020, 00:00

  • PGI4 RETROSPECTIVE STUDY OF DOSE ESCALATION WITH ADALIMUMAB, INFLIXIMAB, AND VEDOLIZUMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

    May 1, 2020, 00:00

  • PIH71 RISK FACTORS ASSOCIATED WITH FALLS AMONG THE ELDERLY IN U.S.: AN ANALYSIS OF MEDICARE CURRENT BENEFICIARY SURVEY DATA

    May 1, 2020, 00:00

  • PMD17 ANALYSIS OF THE COST-EFFECTIVENESS OF ENDOVASCULAR AORTIC REPAIR WITH OFF-THE-SHELF ENDOGRAFTS AS ALTERNATIVE TO CUSTOM-MADE ENDOGRAFTS IN PRIVATE HEALTH INSURANCE IN BRAZIL

    May 1, 2020, 00:00

  • PIH53 PHARMACISTS' INTERVENTIONS IN TRANSITIONS OF CARE: EVALUATING THE FINANCIAL AND CLINICAL IMPLICATIONS FOR LONG-TERM CARE

    May 1, 2020, 00:00

  • PIN89 REGIMEN DURABILITY AMONG HEAVILY TREATMENT-EXPERIENCED (HTE) COMPARED TO NON-HTE TREATMENT-EXPERIENCED HIV PATIENTS IN THE OPERA COHORT

    May 1, 2020, 00:00

  • PDB26 ESTIMATED RENAL AND CARDIOVASCULAR OUTCOMES AND COST OFFSETS IN PATIENTS WITH TYPE 2 DIABETES (T2D) AND DIABETIC NEPHROPATHY (DKD) TREATED WITH CANAGLIFLOZIN

    May 1, 2020, 00:00

  • PMH15 THE CHANGES OF DEPRESSION COSTS AFTER AN INTERNET-DELIVERED COGNITIVE BEHAVIOUR THERAPIES (IDCBT) PRELIMINARY DATA FROM RWD ECONOMIC MODEL

    May 1, 2020, 00:00

  • PIN70 COST OF BLOOD AND BODY FLUID OCCUPATIONAL EXPOSURE MANAGEMENT IN CHINA

    May 1, 2020, 00:00

  • PIN55 ASSOCIATION OF GEOGRAPHIC FACTORS AND SOCIAL DETERMINANTS WITH HERPES ZOSTER VACCINATION

    May 1, 2020, 00:00

  • PDG51 PREVALENCE AND RELATIVE PREDICTIVE VALUE OF DEMOGRAPHIC AND PAIN CHARACTERISTICS FOR OPIOID USE AMONG A NATIONAL SAMPLE OF COMMUNITY-BASED OLDER ADULTS WITH PAIN IN THE UNITED STATES

    May 1, 2020, 00:00

  • PDB23 EXLORATION IN HEALTHCARE RESOURCE UTILIZATION (HCRU) STUDY USING EMR DATABASE AND CLAIMS DATA

    May 1, 2020, 00:00

  • PDB24 ANNUAL HEALTH INSURANCE TREATMENT COST OF NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH NEUROLOGICAL COMPLICATIONS BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00

  • PMS81 PRESCRIPTION DRUG COVERAGE TYPE, OUT-OF-POCKET SPENDING, AND COST-RELATED NONADHERENCE AMONG MEDICARE BENEFICIARIES WITH RHEUMATOID ARTHRITIS

    May 1, 2020, 00:00

  • PMS75 PATIENT- AND PHYSICIAN-IDENTIFIED FACTORS GUIDING TREATMENT CHOICE IN KNEE OSTEOARTHRITIS AND PATIENT PREFERENCE FOR INTRA-ARTICULAR THERAPY

    May 1, 2020, 00:00

  • PDG6 HEALTH JUDICIALIZATION IN BRAZIL: IMPACT OF MIGLUSTATE MEDICINE OBLIGATION FOR PATIENTS WITHOUT OFFICIAL INDICATION OF USE, IN 2019 IN BRAZIL

    May 1, 2020, 00:00

  • Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing

    May 1, 2020, 00:00

  • PDB21 EVALUATION OF THE ONE-YEAR EFFICIENCY OF THE EDUC@DOM TELEMONITORING AND TELE-EDUCATION PROGRAM FOR TYPE 2 DIABETIC PATIENTS

    May 1, 2020, 00:00

  • PDB107 ASSESSING ASYMMETRICAL PRESCRIBING OF ANTIDIABETIC DRUGS RELATIVE TO DIAGNOSIS OF NAFLD

    May 1, 2020, 00:00

  • PGI20 THE IMPACT OF ULCERATIVE COLITIS ON WORK PRODUCTIVITY: A SYSTEMATIC LITERATURE REVIEW

    May 1, 2020, 00:00

  • PMS95 RHEUMATOID ARTHRITIS TREATMENT PROFILE IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

    May 1, 2020, 00:00

  • Mental Health - Health Technology Assessment

    May 1, 2020, 00:00

  • Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy

    May 1, 2020, 00:00

  • Alternative Medicine Information Systems

    May 1, 2020, 00:00

  • PIN14 UPDATING THE CMS MAJOR DIAGNOSTIC CATEGORIES (MDC) TO ALIGN WITH A PATHOPHYSIOLOGICAL MODEL OF DISEASE: IMPLICATIONS FOR RESEARCH AND CLINICAL CARE RESOURCE ALLOCATION

    May 1, 2020, 00:00

  • Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019

    May 1, 2020, 00:00

  • PMD34 DEEP JOINT INFECTION COMPARISON BETWEEN SIMULTANEOUS AND STAGED BILATERAL TOTAL KNEE ARTHROPLASTY

    May 1, 2020, 00:00

  • PMU19 FIRST LINE TREATMENT WITH NATALIZUMAB REDUCES HEALTHCARE RESOURCE USE AND IMPAIRMENT OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS COMPARED TO NATALIZUMAB DELAYED USE

    May 1, 2020, 00:00

  • PMU8 EVALUATION OF THE IMPACT OF AN INPATIENT DISCHARGE CARE PLANNING INTERVENTION ON HOSPITAL 30-DAY READMISSIONS AND COSTS IN A MEDICARE POPULATION

    May 1, 2020, 00:00

  • PIH38 MEASURING A RISK OF AND FACTORS ASSOCIATED WITH IN-HOME TOBACCO SMOKE EXPOSURE IN A US PEDIATRIC SAMPLE: HOUSEHOLD ECONOMICS AND VOLATILE ORGANIC COMPOUND METABOLITE DETECTION

    May 1, 2020, 00:00

  • PMS61 DISABILITY AND DEPRESSION IN LOW BACK PAIN. EVIDENCE FROM A COHORT STUDY

    May 1, 2020, 00:00

  • PDB47 ANNUAL HEALTH INSURANCE TREATMENT COST OF NON-INSULIN-DEPENDENT DIABETES WITH COMPLICATIONS BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00

  • PMH33 VARIATION IN TREATMENT PERSISTENCE BETWEEN ACUTE AND CHRONIC OPIOID USERS RECEIVING BUPRENORPHINE PRODUCTS FOR OPIOID USE DISORDER

    May 1, 2020, 00:00

  • PMS20 COST EFFECTIVENESS OF VIRTUAL REALITY GAME VERSUS CLINIC BASED MCKENZIE EXTENSION THERAPY FOR CHRONIC NON SPECIFIC LOW BACK PAIN

    May 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Real World Data Information Systems

    May 1, 2020, 00:00

  • PGI16 BREAKDOWN OF COSTS ATTRIBUTABLE TO CLOSTRIDIOIDES DIFFICILE INFECTION IN THE US: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW

    May 1, 2020, 00:00

  • PMU56 IMPACT OF FDA APPROVAL OF NEW AGENTS ON THERAPEUTIC OPTIONS FOR GENETIC VARIANTS IN PEDIATRIC TUMORS

    May 1, 2020, 00:00

  • PIH76 ITCH REPORTED OUTCOME TOOL FOR CAREGIVERS OF PEDIATRIC PATIENTS WITH CHOLESTATIC LIVER DISEASE: AN ANALYSIS OF VALIDATION AND SCORING FROM THE ICONIC MARALIXIBAT STUDY

    May 1, 2020, 00:00

  • PDB73 EPIDEMIOLOGICAL DISEASE BURDEN OF DIABETIC POLYNEUROPATHY BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PMH39 ECONOMIC BURDEN ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER, GLOBAL ANXIETY DISORDER, AND POLY-NONCOMMUNICABLE CHRONIC DISEASE (NCCD) COMORBIDITY

    May 1, 2020, 00:00

  • PMU41 PREVALENCE AND ASSOCIATED FACTORS TO SUICIDE ATTEMPTS IN LOW-INCOME ADOLESCENTS FROM THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PDB28 QUALITY ADJUSTED LIFE YEARS (QALYS) IN THE DIABETES PREVENTION PROGRAM (DPP) USING QUALITY OF WELL BEING (QWB) AND SF-6D INSTRUMENTS IN SAME SAMPLE: COMPLETE CASE ANALYSIS

    May 1, 2020, 00:00

  • PDG46 OUTPATIENT OFF-LABEL GABAPENTIN UTILIZATION FROM 2011 TO 2015 AMONG UNITED STATES ADULTS

    May 1, 2020, 00:00

  • PMH34 INTEGRATING COUNTY-LEVEL HEALTH, HUMAN SERVICES, AND CRIMINAL JUSTICE DATA TO PREDICT RISK OF OPIOID OVERDOSE AMONG MEDICAID BENEFICIARIES: A MACHINE LEARNING APPROACH

    May 1, 2020, 00:00

  • PCN13 FACTORS THAT MODIFY THE EFFECT OF MONO- OR COMBINATION PD-1/PD-L1 INHIBITOR THERAPIES ON SURVIVAL OUTCOMES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00

  • PMD23 ANALYSIS OF THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE REPLACEMENT AS ALTERNATIVE TO SURGICAL AORTIC VALVE REPLACEMENT IN PRIVATE HEALTH INSURANCE IN BRAZIL

    May 1, 2020, 00:00

  • PMS51 GABAPENTIN, OPIOID, AND BENZODIAZEPINE PRESCRIBING IN EARLY CARE OF INDIVIDUALS WITH CHRONIC BACK PAIN: A SECULAR TRENDS ANALYSIS

    May 1, 2020, 00:00

  • PIN78 CHARACTERIZATION OF UNNECESSARY EMERGENCY DEPARTMENT ENCOUNTERS FOR RABIES POSTEXPOSURE PROPHYLAXIS VACCINATION

    May 1, 2020, 00:00

  • PDB53 TRENDS IN PRICES OF INSULIN MARKETED IN THE US (1984-2020)

    May 1, 2020, 00:00

  • PIN62 PREVALENCE AND FACTORS ASSOCIATED WITH NEVER-VACCINATED CHILDREN AGED 12-59 MONTHS IN ETHIOPIA. A MULTILEVEL ANALYSIS OF THE INDIVIDUAL AND CONTEXTUAL FACTORS

    May 1, 2020, 00:00

  • AI4 CAN WE DECREASE THE SCREENING BURDEN IN SYSTEMATIC REVIEWS? PERFORMANCE OF TWO NATURAL LANGUAGE PROCESSORS TO EXCLUDE RECORDS

    May 1, 2020, 00:00

  • PMU3 EFFECTIVENESS OF IMPLEMENTATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN INDIA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00

  • PCN9 TARGETED LITERATURE REVIEW (TLR) OF THE REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG MCRPC PATIENTS IN THE US

    May 1, 2020, 00:00

  • PMU46 PSYCHOTROPIC POLYPHARMACY AMONG CHILDREN, ADOLESCENTS, AND YOUNG ADULTS TREATED WITH ANTIDEPRESSANTS IN THE UNITED STATES

    May 1, 2020, 00:00

  • PCN4 ACCURACY OF LIFE YEAR GAIN PREDICTIONS FOR NIVOLUMAB MONOTHERAPY IN THE LONG TERM: AN ANALYSIS ACROSS FOUR INDICATIONS

    May 1, 2020, 00:00

  • PCN2 PROJECTED LIFETIME CLINICAL VALUE OF A MULTICANCER EARLY DETECTION TEST

    May 1, 2020, 00:00

  • Cost-Effectiveness Studies

    May 1, 2020, 00:00

  • PIN12 THE COST-EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHINESE CITIES

    May 1, 2020, 00:00

  • Injury Information Systems

    May 1, 2020, 00:00

  • PBI11 TRENDS IN LIST PRICES, NET PRICES, AND DISCOUNTS FOR SELF-ADMINISTERED DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Health Policy Regulatory

    May 1, 2020, 00:00

  • PIH48 DIFFERENTIAL PRESCRIPTION PATTERNS OF DROSPIRENONE-CONTAINING COMBINED ORAL CONTRACEPTIVES IN EUROPE AND NORTH AMERICA - INSIGHTS FROM THE INAS-FOCUS STUDY

    May 1, 2020, 00:00

  • CC2 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING AND TREATMENT FOR SPINAL MUSCULAR ATROPHY

    May 1, 2020, 00:00

  • PDB8 STUDY ON STANDARD CRITERIA OF SERUM URIC ACID AND FACTORS OF HIGH URIC ACID IN CHILDREN USING CLAIMS DATABASE IN JAPAN

    May 1, 2020, 00:00

  • PMS6 EFFECTIVENESS AND ACCEPTABILITY OF AMITRIPTYLINE AND FOOD AND DRUG ADMINISTRATION-APPROVED TREATMENTS FOR FIBROMYALGIA: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00

  • PBI32 EVOLUTION OF THE COST OF MEDICINES ACQUIRED BY THE COSTA RICAN SOCIAL SECURITY SYSTEM (CCSS) ACCORDINGLY TO ITS ORIGIN: BIOLOGICAL OR CHEMICAL SYNTHESIS

    May 1, 2020, 00:00

  • PMH56 FITTING ITEM RESPONSE THEORY MODEL TO DETERMINE THE PSYCHOMETRIC PROPERTIES OF KESSLER PSYCHOLOGICAL DISTRESS SCALE AMONG WOMEN WHO EXCHANGE SEX

    May 1, 2020, 00:00

  • PDB89 OBESITY PUBLICATION PATTERNS OVER 20 YEARS: WEIGHING DOWN OBESITY DRUG AVAILABILITY?

    May 1, 2020, 00:00

  • PDB97 DISEASE STATE AWARENESS AND ITS IMPACT ON DISEASE MANAGEMENT IN PATIENTS WITH TYPE 2 DIABETES IN QUETTA, PAKISTAN.

    May 1, 2020, 00:00

  • Alternative Medicine Nutrition - Medical Technologies

    May 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Patient-Centered Research

    May 1, 2020, 00:00

  • PIH54 PROVISION OF CONTRACEPTIVES AS A MARKER OF POST-PARTUM QUALITY OF CARE AMONG WOMEN ENROLLED IN MEDICAID

    May 1, 2020, 00:00

  • PMH13 ANALYZING TRENDS IN MEDICAL EXPENDITURES ASSOCIATED WITH ALZHEIMER'S DISEASE AMONG U.S. ADULTS WITH DIABETES: 2013-2017

    May 1, 2020, 00:00

  • Individual's Health - Patient-Centered Research

    May 1, 2020, 00:00

  • Gastrointestinal Disorders - Methodological Statistical Research

    May 1, 2020, 00:00

  • Injury Trauma - Patient-Centered Research

    May 1, 2020, 00:00

  • PDB40 COST-EFFECTIVENESS ANALYSIS OF SENSOR-AUGMENTED PUMP IN TYPE 1 DIABETES MELLITUS COMPARED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE RUSSIAN FEDERATION

    May 1, 2020, 00:00

  • Drugs Generics - Organizational Practices

    May 1, 2020, 00:00

  • PIN7 REAL-WORLD EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS (DAA) IN YOUNG ADULT (18-25) AND ELDERLY (80+) POPULATIONS WITH HEPATITIS C (HCV)

    May 1, 2020, 00:00

  • PMH10 DETERMINANTS, TRENDS, AND COSTS ASSOCIATED WITH 30-DAY ALL-CAUSE READMISSION IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH SUICIDAL IDEATION USING THE NATIONWIDE READMISSION DATABASE

    May 1, 2020, 00:00

  • PMU5 PREVALENCE AND ASSOCIATED FACTORS TO PSYCHOTIC SUBSTANCE USE IN LOW-INCOME ADOLESCENTS FROM THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PIH42 RECURRENT VAGINITIS AND CANDIDIASIS: BURDEN AMONG COMMERCIALLY INSURED WOMEN WITH TYPE II DIABETES IN THE US

    May 1, 2020, 00:00

  • PAM11 DEVELOPMENT AND EVALUATION OF THE BLOOD DEFICIENCY QUESTIONNAIRE (BDQ)

    May 1, 2020, 00:00

  • PIT4 ECONOMIC BURDEN OF HOSPITALIZATIONS RELATED TO MAJOR AND MEDIUM BURN INJURIES IN BRAZIL

    May 1, 2020, 00:00

  • PMS45 CLINICAL CHARACTERISTICS AND HEALTH OUTCOMES IN A GROUP OF ELDERLY PATIENTS WITH HIP FRACTURE IN MANIZALES, COLOMBIA.

    May 1, 2020, 00:00

  • PIH47 DEMENTIA SEVERITY AND OPIOID USE IN LONG-TERM CARE NURSING HOME RESIDENTS

    May 1, 2020, 00:00

  • PDB4 SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF THE EFFECT OF NALTREXONE/ BUPROPION COMPARED WITH OTHER ANTI-OBESITY DRUGS IN OVERWEIGHT AND OBESE PATIENTS

    May 1, 2020, 00:00

  • PMH40 TRENDS IN ATYPICAL ANTIPSYCHOTIC MEDICATION USE IN US ADULTS

    May 1, 2020, 00:00

  • PMD10 A BUDGET IMPACT AND RETURN ON INVESTMENT ANALYSIS OF INCORPORATING DRUG – ELUTING STENTS INTO A CHINESE HOSPITAL MEDICAL DEVICE FORMULARY — A HOSPITAL PERSPECTIVE

    May 1, 2020, 00:00

  • PMS58 EPIDEMIOLOGICAL DISEASE BURDEN OF INJURIES TO THE ELBOW AND FOREARM BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PDG48 PRESCRIBING PRACTICES FOR HYPERLIPIDEMIA AMONG U.S. AMBULATORY PATIENTS

    May 1, 2020, 00:00

  • PCV60 PREVALENCE, RISK FACTORS, AND MANAGEMENT OF UNCONTROLLED HYPERTENSION AMONG DIABETIC PATIENTS: A HOSPITAL-BASED CROSS-SECTIONAL STUDY

    May 1, 2020, 00:00

  • Mental Health - Real World Data Information Systems

    May 1, 2020, 00:00

  • PIN8 HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL

    May 1, 2020, 00:00

  • AI2 PREDICTORS OF PARKINSON DISEASE IN A MEDICARE POPULATION: AN APPLICATION OF MACHINE LEARNING IN EARLY DISEASE DETECTION

    May 1, 2020, 00:00

  • PCV78 ASSESSMENT OF HEALTH LITERACY AND THERAPEUTIC ADHERENCE AMONG PATIENTS WITH HYPERTENSION

    May 1, 2020, 00:00

  • PMU65 EVALUATION OF HOME HEALTH FOR PATIENTS ELIGIBLE FOR THE POST-ACUTE CARE TRANSFER POLICY

    May 1, 2020, 00:00

  • PDG49 DETERMINANTS OF NON-PHARMACOLOGIC THERAPY, OPIOID, NON-OPIOID/OPIOID COMBINATION, AND NON-OPIOID MEDICATIONS IN OUTPATIENTS WITH NONMALIGNANT CHRONIC PAIN USING RECENT NATIONAL SURVEY

    May 1, 2020, 00:00

  • Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling

    May 1, 2020, 00:00

  • PCV75 IDENTIFYING APPROPIATE HOSPITALS FOR PATIENT RECRUITMENT IN CLINICAL TRIALS FOR CANADA USING MACHINE LEARNING ALGORITHMS

    May 1, 2020, 00:00

  • Individual's Health - Real World Data Information Systems

    May 1, 2020, 00:00

  • Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the ISPOR Personalized Precision Medicine Special Interest Group [Editor's Choice]

    May 1, 2020, 00:00

  • Infectious Diseases - Methodological Statistical Research

    May 1, 2020, 00:00

  • PIH37 INEQUALITY OF OPPORTUNITY IN MATERNAL HEALTH AMONG ADOLESCENTS

    May 1, 2020, 00:00

  • PIN19 A COST EFFECTIVENESS ANALYSIS OF ACTIVE CASE FINDING AND PASSIVE CASE FINDING FOR CASE DETECTION OF TUBERCULOSIS AT KISUGU HC III,KAMPALA UGANDA.

    May 1, 2020, 00:00

  • PMU59 GLOBAL OUTCOMES-BASED CONTRACTING TRENDS IN THE US AND EUROPE OVER THE PAST 5 YEARS

    May 1, 2020, 00:00

  • Injury Regulatory

    May 1, 2020, 00:00

  • PIH7 ANNUAL HEALTH INSURANCE TREATMENT COST OF CERVICAL CANCER BASED ON ROUTINELY COLLECTED NATIONWIDE REAL-WORLD FINANCING DATA IN HUNGARY

    May 1, 2020, 00:00

  • PMH12 TRAJECTORY IN HYPNOTIC DRUG USE, SELF-PERCEIVED HEALTH, AND HEALTHCARE EXPENDITURES AMONG PATIENTS DIAGNOSED WITH ANXIETY DISORDERS

    May 1, 2020, 00:00

  • Patient Behavior Studies

    May 1, 2020, 00:00

  • PCV76 IDENTIFYING KNOWLEDGE GAPS IN HEART FAILURE (HF) RESEARCH AMONG WOMEN USING UNSUPERVISED MACHINE LEARNING METHODS

    May 1, 2020, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Patient-Centered Research

    May 1, 2020, 00:00

  • PIH58 GEOGRAPHICAL DISPARITIES IN NON-UTILIZATION OF HEALTH FACILITY DELIVERY AND POSTNATAL SERVICES IN GHANA

    May 1, 2020, 00:00

  • Multiple Diseases - Epidemiology Public Health

    May 1, 2020, 00:00

  • Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials

    May 1, 2020, 00:00

  • PIN76 CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C TREATED UNDER A NEW STANDARD OF CARE

    May 1, 2020, 00:00

  • Mental Health - Methodological Statistical Research

    May 1, 2020, 00:00

  • PIH70 FORMATIVE RESEARCH TO DEVELOP A CLINICAL TRIAL DECISION AID THAT INTEGRATES QUANTITATIVE PATIENT PREFERENCE DATA

    May 1, 2020, 00:00

  • PDB18 ASSESSMENT OF THE HEALTH CARE UTILIZATION AND ECONOMIC BURDEN ON DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE US VETERANS HEALTH ADMINISTRATION POPULATION

    May 1, 2020, 00:00

  • PDG75 PREVALENCE AND FACTORS ASSOCIATED WITH ANTIEPILEPTIC DRUG USE IN NURSING HOME RESIDENTS WITH PAIN

    May 1, 2020, 00:00

  • PDB68 CHARACTERISTICS OF PATIENTS WITH SEVERE HYPOGLYCEMIA AMONG PATIENTS WITH DIABETES USING INSULIN IN COMMERCIALLY INSURED, MEDICARE, AND MEDICAID POPULATION

    May 1, 2020, 00:00

  • PDB50 ANNUAL HEALTH INSURANCE TREATMENT COST OF DIABETIC POLYNEUROPATHY BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00

  • PMH60 SURVEY OF PATIENT EXPERIENCE AND BURDEN OF ILLNESS IN WOMEN WITH POSTPARTUM DEPRESSION

    May 1, 2020, 00:00

  • PIH29 ECONOMIC BURDEN OF ENDOMETRIOSIS: A SYSTEMATIC LITERATURE REVIEW

    May 1, 2020, 00:00

  • PIH21 EFFICACY AND SAFETY OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN PATIENTS WITH OSTEOARTHRITIS: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00

  • PMH11 LONG-TERM MEDICATION-ASSISTED TREATMENT OF OPIOID USE DISORDER IN THE UNITED STATES: A COST-UTILITY ANALYSIS

    May 1, 2020, 00:00

  • PBI31 MANAGED ENTRY AGREEMENTS FOR ATMPS DESPITE ACCESS ALREADY GRANTED? THE CASE OF GERMANY

    May 1, 2020, 00:00

  • PMU60 DO COMPANIES SEQUENCE THE LAUNCH OF INDICATIONS FOR MULTI-INDICATION PRODUCTS?

    May 1, 2020, 00:00

  • PDG14 BUDGET IMPACT ANALYSIS OF GIPAP AND VPAP TERMINATION WITHIN THE NEXT 5 YEARS IN VIETNAM

    May 1, 2020, 00:00

  • PIN21 ESTABLISH A PHARMACEUTICAL CARE MODE FOR THERAPEUTIC DRUG MONITORING OF VANCOMYCIN AND EVALUATE ITS EFFECTIVENESS AND ECONOMICS

    May 1, 2020, 00:00

  • PDB95 FACTORS ASSOCIATED WITH MEDICATION NON-ADHERENCE AMONG MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES

    May 1, 2020, 00:00

  • Cardiovascular Disorders - Real World Data Information Systems

    May 1, 2020, 00:00

  • PDG41 CLOSURE OF THE PART D COVERAGE GAP AND OUT-OF-POCKET COSTS FOR RHEUMATOID ARTHRITIS BIOLOGICS IN MEDICARE PART D

    May 1, 2020, 00:00

  • PGI26 THE COST-EFFECTIVENESS OF PHARMACOLOGIC VS SURGICAL INTERVENTION FOR PATIENTS HOSPITALIZED WITH ACUTE SEVERE ULCERATIVE COLITIS IN THE UNITED STATES

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Real World Data Information Systems

    May 1, 2020, 00:00

  • Competing Views on the English EQ-5D-5L Valuation Set [Editor's Choice]

    May 1, 2020, 00:00

  • PGI36 ESTIMATION OF THE MINIMAL IMPORTANT DIFFERENCES IN EUROQOL-5 DIMENSIONS (EQ-5D) FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION

    May 1, 2020, 00:00

  • Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions

    May 1, 2020, 00:00

  • PMD32 RISK AND OUTCOMES FOLLOWING APPLICATION OF MULTI-PLANAR RING FIXATION SYSTEMS - A TWELVE YEAR REVIEW FROM A US CLAIMS DATABASE ANALYSIS

    May 1, 2020, 00:00

  • PIN87 PATIENT ENGAGEMENT IN HIV CARE MANAGEMENT: BEHAVIOR ECONOMICS OF ART ADHERENCE AND ESTABLISHING CARE VISITS

    May 1, 2020, 00:00

  • PIH31 INVERSE RELATIONSHIP BETWEEN ANEMIA IN THE THIRD TRIMESTER OF PREGNANCY AND LOW BIRTH WEIGHT IN A REFERENCE MATERNITY UNIT OF A CARRIBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PMU44 PREVALENCE OF MULTIMORBIDITY AMONG ASIAN INDIANS, CHINESE, AND NON-HISPANIC WHITES IN THE UNITED STATES

    May 1, 2020, 00:00

  • PMS40 REAL-WORLD TREATMENT PATTERNS AND ECONOMIC BURDEN OF ROTATOR CUFF TEAR PATIENTS IN THE US

    May 1, 2020, 00:00

  • PCV57 THE BURDEN OF HEART FAILURE IN NORTH AMERICA AND WESTERN EUROPE

    May 1, 2020, 00:00

  • PMH46 GEOGRAPHIC VARIATION IN TREATMENT ADMISSIONS FOR OPIOID USE DISORDER IN CINCINNATI COMPARED TO THE UNITED STATES

    May 1, 2020, 00:00

  • PIN69 NOW OR LATER: THE COST BURDEN OF HCV INFECTION VS. TREATMENT FOR MEDICARE AND MEDICAID POPULATIONS

    May 1, 2020, 00:00

  • Medical Devices - Health Policy Regulatory

    May 1, 2020, 00:00

  • Infectious Diseases - Real World Data Information Systems

    May 1, 2020, 00:00

  • PMS7 THE ROLE OF SPECIALIZED PRO-RESOLVING LIPID MEDIATORS IN THE TREATMENT OF INFLAMMATION CAUSED BY EXERCISING: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • PGI35 REAL-WORLD MEDICATION USE AND COST OF ILLNESS IN IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN THE CHINESE SETTING

    May 1, 2020, 00:00

  • PIN20 SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEPATITIS C

    May 1, 2020, 00:00

  • PIH43 SEXUAL BEHAVIOR, USE OF CONTRACEPTIVE METHODS AND PREGNANCY IN YOUNG PEOPLE FROM A POPULATION AFFILIATED IN A HEALTH INSURER COMPANY IN COLOMBIA 2018

    May 1, 2020, 00:00

  • PMU11 ASSOCIATION BETWEEN DEPRESSION AND HEALTHCARE EXPENDITURES AMONG STROKE SURVIVORS

    May 1, 2020, 00:00

  • PMU6 EFFECTIVENESS OF A NATIVE TYPE I COLLAGEN MATRIX PLUS POLYHEXAMETHYLENE BIGUANIDE ANTIMICROBIAL (PHMB) FOR THE TREATMENT OF CUTANEOUS WOUNDS IN A REAL WORLD SETTING

    May 1, 2020, 00:00

  • PDB32 COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING

    May 1, 2020, 00:00

  • PMS65 A VISUAL ANALYTICAL APPROACH TO UNDERSTANDING TREATMENT PATTERNS AMONG TREATMENT-NAÏVE RHEUMATOID ARTHRITIS PATIENTS WITH BIOLOGIC USE IN THE US VETERANS HEALTH ADMINISTRATION DATABASE

    May 1, 2020, 00:00

  • PMU39 COOKING AT HOME CAN SAVE MONEY, REGARDLESS OF FOOD PRICE: A MULTILEVEL ANALYSIS OF MEALS PREPARED AWAY FROM THE HOME ON DIET MEASURES AND FOOD EXPENDITURES

    May 1, 2020, 00:00

  • PMH63 HUMANISTIC BURDEN ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER AND GLOBAL ANXIETY DISORDER AMONG ADULTS WITH NON-COMMUNICABLE DISEASES (NCCDS) IN THE UNITED STATES

    May 1, 2020, 00:00

  • PMS52 EPIDEMIOLOGY OF DERMATITIS ATOPIC IN AMERICA: SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • PIH35 LONG-TERM PRESCRIPTION OPIOID USE AMONG OLDER ADULTS IN THE UNITED STATES

    May 1, 2020, 00:00

  • PDG47 OUTPATIENT OPIOID PRESCRIBING AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS OF NATIONAL AMBULATORY MEDICAL CARE SURVEY, 2011-2016

    May 1, 2020, 00:00

  • PCN15 EFFICACY, EFFECTIVENESS, AND SAFETY OF FRONTLINE TREATMENTS FOR PERIPHERAL T-CELL LYMPHOMA

    May 1, 2020, 00:00

  • PGI23 TREATMENT COST ANALYSIS FOR PATIENTS IN THE UNITED STATES WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE AN INADEQUATE RESPONSE OR WHO ARE INTOLERANT TO TNF BLOCKERS

    May 1, 2020, 00:00

  • Editorial Board

    Apr 21, 2020, 08:38

  • Public Attitudes on Lung Cancer Screening and Radiation Risk: A Best-Worst Experiment

    Apr 1, 2020, 00:00

  • Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications

    Apr 1, 2020, 00:00

  • A Systematic Review of the Feasibility and Psychometric Properties of the ICEpop CAPability Measure for Adults and Its Use So Far in Economic Evaluation

    Apr 1, 2020, 00:00

  • Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France

    Apr 1, 2020, 00:00

  • Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report [Editor's Choice]

    Apr 1, 2020, 00:00

  • Table of Contents

    Apr 1, 2020, 00:00

  • Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts

    Apr 1, 2020, 00:00

  • Are Value-Based Arrangements the Answer We’ve Been Waiting for?

    Apr 1, 2020, 00:00

  • Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match? [Editor's Choice]

    Apr 1, 2020, 00:00

  • Is There a Future for Value-Based Contracting? [Editor's Choice]

    Apr 1, 2020, 00:00

  • Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users

    Apr 1, 2020, 00:00

  • Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim

    Apr 1, 2020, 00:00

  • Copyright/Subscription

    Apr 1, 2020, 00:00

  • Reporting Quality of Discrete Event Simulations in Healthcare—Results From a Generic Reporting Checklist

    Apr 1, 2020, 00:00

  • Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead

    Apr 1, 2020, 00:00

  • Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

    Apr 1, 2020, 00:00

  • Managed Entry Agreements: Policy Analysis From the European Perspective [Editor's Choice]

    Apr 1, 2020, 00:00

  • Editorial Board

    Mar 18, 2020, 10:02

  • Author's Reply

    Mar 1, 2020, 00:00

  • Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis

    Mar 1, 2020, 00:00

  • Socioeconomic Status of Newborns and Hospital Efficiency: Implications for Hospital Payment Methods

    Mar 1, 2020, 00:00

  • How Are Debriefing Questions Used in Health Discrete Choice Experiments? An Online Survey

    Mar 1, 2020, 00:00

  • Mapping WOMAC Onto the EQ-5D-5L Utility Index in Patients With Hip or Knee Osteoarthritis

    Mar 1, 2020, 00:00

  • Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?

    Mar 1, 2020, 00:00

  • Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting [Editor's Choice]

    Mar 1, 2020, 00:00

  • Moving Beyond the Tip of the Iceberg to Incorporate Patients’ Perspectives and Outcomes in the Medical Device Regulatory Process

    Mar 1, 2020, 00:00

  • Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation

    Mar 1, 2020, 00:00

  • Table of Contents

    Mar 1, 2020, 00:00

  • A Step Closer to Better Research Prioritization? The ISPOR Value of Information Task Force Reports

    Mar 1, 2020, 00:00

  • Measuring Quality-Adjusted Life-Years When Health Fluctuates

    Mar 1, 2020, 00:00

  • Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs [Editor's Choice]

    Mar 1, 2020, 00:00

  • Psychometric Analysis of the Abdominal Score From the Diary for Irritable Bowel Syndrome Symptoms–Constipation Using Phase IIb Clinical Trial Data

    Mar 1, 2020, 00:00

  • Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force [Editor's Choice]

    Mar 1, 2020, 00:00

  • Integrating the Voice of the Patient Into the Medical Device Regulatory Process Using Patient Preference Information

    Mar 1, 2020, 00:00

  • Letter to the Editor: Methods for Measuring Multiple Medication Adherence: A Systematic Review

    Mar 1, 2020, 00:00

  • Subscription Page

    Mar 1, 2020, 00:00

  • Computing PROPr Utility Scores for PROMIS® Profile Instruments

    Mar 1, 2020, 00:00

  • Economic Evaluation of User-Fee Exemption Policies for Maternal Healthcare in Burkina Faso: Evidence From a Cost-Effectiveness Analysis

    Mar 1, 2020, 00:00

  • Exploratory Factor Analysis of a Patient-Centered Cancer Care Measure to Support Improved Assessment of Patients’ Experiences

    Mar 1, 2020, 00:00

  • Editorial Board

    Feb 27, 2020, 10:34

  • Health-Related Quality of Life in Children With Low Language or Congenital Hearing Loss, as Measured by the PedsQL and Health Utility Index Mark 3

    Feb 1, 2020, 00:00

  • “Stick or Twist?” Negotiating Price and Data in an Era of Conditional Approval

    Feb 1, 2020, 00:00

  • Copyright/Subscription

    Feb 1, 2020, 00:00

  • Why Reinvent the Wheel? Use or Modification of Existing Clinical Outcome Assessment Tools in Medical Product Development [Editor's Choice]

    Feb 1, 2020, 00:00

  • Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

    Feb 1, 2020, 00:00

  • Value-Based Pharmaceutical Contracts: Value for Whom?

    Feb 1, 2020, 00:00

  • Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation

    Feb 1, 2020, 00:00

  • Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana

    Feb 1, 2020, 00:00

  • Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example

    Feb 1, 2020, 00:00

  • Clinical Effectiveness of Decision Support for Prescribing Opioids for Chronic Noncancer Pain: A Prospective Cohort Study

    Feb 1, 2020, 00:00

  • Table of Contents

    Feb 1, 2020, 00:00

  • Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force

    Feb 1, 2020, 00:00

  • Optimal Design of Population-Level Financial Incentives of Influenza Vaccination for the Elderly

    Feb 1, 2020, 00:00

  • A Head-On Ordinal Comparison of the Composite Time Trade-Off and the Better-Than-Dead Method

    Feb 1, 2020, 00:00

  • Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems [Editor's Choice]

    Feb 1, 2020, 00:00

  • Effects of Lean Healthcare on Patient Flow: A Systematic Review

    Feb 1, 2020, 00:00

  • What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis

    Feb 1, 2020, 00:00

  • To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland

    Feb 1, 2020, 00:00

  • Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions [Editor's Choice]

    Feb 1, 2020, 00:00

  • Author's Reply

    Feb 1, 2020, 00:00

  • Editorial Board

    Jan 15, 2020, 08:20

  • Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review

    Jan 1, 2020, 00:00

  • Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review

    Jan 1, 2020, 00:00

  • Copyright/Subscription

    Jan 1, 2020, 00:00

  • Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis [Editor's Choice]

    Jan 1, 2020, 00:00

  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

    Jan 1, 2020, 00:00

  • Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations

    Jan 1, 2020, 00:00

  • Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis [Editor's Choice]

    Jan 1, 2020, 00:00

  • Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System

    Jan 1, 2020, 00:00

  • Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary

    Jan 1, 2020, 00:00

  • A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C

    Jan 1, 2020, 00:00

  • HTA Around the World: Broadening Our Understanding of Cross-Country Differences [Editor's Choice]

    Jan 1, 2020, 00:00

  • Costs and Benefits of Alternative Strategies to Control the Spread of Livestock-Acquired Methicillin-Resistant Staphylococcus Aureus From Pig Production

    Jan 1, 2020, 00:00

  • Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands

    Jan 1, 2020, 00:00

  • Table of Contents

    Jan 1, 2020, 00:00

  • Development of System Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada

    Jan 1, 2020, 00:00

  • Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?

    Jan 1, 2020, 00:00

  • Concepts and Instruments for Patient-Reported Outcome Assessment in Celiac Disease: Literature Review and Experts’ Perspectives

    Jan 1, 2020, 00:00

  • The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review

    Jan 1, 2020, 00:00

  • Disclosure Information

    Dec 17, 2019, 09:25

  • Editorial Board

    Dec 3, 2019, 08:15

  • Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

    Dec 1, 2019, 00:00

  • Table of Contents

    Dec 1, 2019, 00:00

  • Excess Costs and Economic Burden of Obesity-Related Cancers in the United States [Editor's Choice]

    Dec 1, 2019, 00:00

  • Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis

    Dec 1, 2019, 00:00

  • Community-Based Services by Pharmacists: A Systematic Review of Cost-Utility Analyses

    Dec 1, 2019, 00:00

  • How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L [Editor's Choice]

    Dec 1, 2019, 00:00

  • Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?

    Dec 1, 2019, 00:00

  • Measuring Productivity Costs in Patients With Musculoskeletal Disorders: Measurement Properties of the Institute for Medical Technology Assessment Productivity Cost Questionnaire

    Dec 1, 2019, 00:00

  • Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study

    Dec 1, 2019, 00:00

  • Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial

    Dec 1, 2019, 00:00

  • Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model

    Dec 1, 2019, 00:00

  • Copyright/Subscription

    Dec 1, 2019, 00:00

  • Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017

    Dec 1, 2019, 00:00

  • Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments? [Editor's Choice]

    Dec 1, 2019, 00:00

  • Carer Social Care-Related Quality of Life Outcomes: Estimating English Preference Weights for the Adult Social Care Outcomes Toolkit for Carers

    Dec 1, 2019, 00:00

  • Cost-Effectiveness of Antihypertensive Therapy in Patients Older Than 80 Years: Cohort Study and Markov Model

    Dec 1, 2019, 00:00

  • Editorial Board

    Nov 13, 2019, 17:52

  • Cardiovascular Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMS52 CLINICAL GUIDELINE DEVELOPMENT FOR THE MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN PRIMARY CARE

    Nov 1, 2019, 00:00

  • PCN370 IMPROVING PATIENT ACCESS TO INNOVATIVE MEDICATIONS WHILE PROTECTING PUBLIC BUDGETS SUSTAINABILITY: AN ALTERNATIVE GO TO MARKET AND PRICING FRAMEWORK TO ENABLE VALUE CO-CREATION BETWEEN PHARMAS AND PAYERS

    Nov 1, 2019, 00:00

  • PCN80 REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2019, 00:00

  • PND26 ECONOMIC BURDEN OF HUNTINGTON'S DISEASE IN EUROPE

    Nov 1, 2019, 00:00

  • PNS273 ICER: SIMILARITIES AND DIFFERENCES BETWEEN UK (ENGLAND) AND USA COST-EFFECTIVENESS WATCHDOGS

    Nov 1, 2019, 00:00

  • PMU29 ECONOMIC EVALUATION FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURES INFECTIONS (ABSSSI) FROM THE NATIONAL PAYER PERSPECTIVE: INTRODUCTION OF A NEW TREATMENT INTO THE PATIENT JOURNEY. SIMULATION IN 3 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PNS182 SYSTEMIC ADMINISTRATION OF GLUCOCORTICOIDS IN GUIZHOU PROVINCE, CHINA: A SURVEY AMONG HOSPITAL PHARMACIES.

    Nov 1, 2019, 00:00

  • PDG79 WAS THE EVIDENCE BASE FOR YESCARTA AND KYMRIAH SUFFICIENT TO JUSTIFY THEIR COST AND SECURE PATIENT ACCESS ACROSS 5 MARKETS?

    Nov 1, 2019, 00:00

  • PCV104 A SYSTEMATIC REVIEW OF ORGANISATIONAL AND SERVICE SPECIFICATION RECOMMENDATIONS FOR CENTRES PROVIDING PERCUTANEOUS CORONARY INTERVENTIONS

    Nov 1, 2019, 00:00

  • PCV152 SELF-ASSESSED FUNCTIONAL CLASS, QUALITY OF LIFE AND HEALTHCARE RESOURCE CONSUMPTION IN PORTUGUESE HEART FAILURE PATIENTS: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • PIH56 PLACE OF COMPLEMENTARY MEDICINES AND OPPORTUNITIES IN THE MANAGEMENT OF GYNECOLOGICAL CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PCN280 CHARACTERIZING THE CONTINUED RELEVANCE OF IRP IN ITALY: A SIMULATION ANALYSIS OF TOP PRESCRIBED MOLECULES IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCV6 BURDEN OF MORTALITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN43 NEW CERVICAL CANCER SCREENING POLICY IN GERMANY - WHAT IS THE IMPACT ON THE BENEFIT-HARM BALANCE?

    Nov 1, 2019, 00:00

  • PMU4 WHAT IS A GOOD OR BAD NUMBER NEED TO TREAT (NNT) VALUE? A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN403 IDENTIFYING KEY CRITERIA FOR HEALTH TECHNOLOGY ASSESSMENT FOR ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL: A MCDA APPROACH

    Nov 1, 2019, 00:00

  • PDG74 AN ANALYSIS OF RESTRICTED RECOMMENDATIONS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • Alternative Medicine Nutrition - Economic Evaluation

    Nov 1, 2019, 00:00

  • PIH61 VALIDATION OF THE STUDY MEDICATION SATISFACTION QUESTIONNAIRE (SMSQ). A MEASURE OF MEDICATION SATISFACTION DESIGNED FOR INDIVIDUALS TAKING PRE-EXPOSURE PROPHYLAXIS (PREP) MEDICATION FOR HIV

    Nov 1, 2019, 00:00

  • PCN266 PATIENT, DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN GREECE: RESULTS FROM ANALYSIS OF A GREEK CLL-DATABASE

    Nov 1, 2019, 00:00

  • PIH40 ASSESSING HEALTH DISPARITY IN THE ELDERLY POPULATION WITH DIFFERENT ECONOMIC STATUS IN SOUTH KOREA: FOCUSING ON HIP FRACTURE

    Nov 1, 2019, 00:00

  • PCN103 A COMPARISON OF PARTITIONED-SURVIVAL AND STATE TRANSITION MODELLING APPROACHES - FINDINGS FROM A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PIN130 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA

    Nov 1, 2019, 00:00

  • PBI67 METHODOLOGICAL DESIGN OF ADVANCED INTERVENTIONAL TRIALS FOR GENE THERAPIES

    Nov 1, 2019, 00:00

  • PCN178 MODELLING THE BUDGET IMPACT OF INTRODUCING 3D MAMMOGRAPHY FOR BREAST CANCER SCREENING IN GERMANY

    Nov 1, 2019, 00:00

  • PDB52 ECONOMIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS347 SCIENTIFIC OUTCOME OF ISPOR CONFERENCES: AN ANALYSIS OF 44,390 ABSTRACTS PRESENTED AT 38 ISPOR CONFERENCES BETWEEN 2002-2018

    Nov 1, 2019, 00:00

  • PCN378 PHARMACOECONOMIC ANALYSIS OF ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

    Nov 1, 2019, 00:00

  • PDB57 COST SAVINGS ASSOCIATED WITH PREMIX VERSUS BASAL-BOLUS REGIMEN IN ALGERIAN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED UNDER BASAL INSULIN REGIMEN

    Nov 1, 2019, 00:00

  • PIN115 ANALYZING SOCIO-ECONOMIC INEQUALITY IN CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA

    Nov 1, 2019, 00:00

  • PDB15 THE COST OF HYPOGLYCAEMIA IN TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN424 NETWORK META-ANALYSIS FOR IMMUNE ONCOLOGY TRIALS USING SPLINES

    Nov 1, 2019, 00:00

  • PNS291 ANALYSIS OF RECALLS OF MEDICAL DEVICES FROM 2009 TO 2018 BY RISK CLASS AND DEVICE CATEGORY BASED ON ITALIAN DATA

    Nov 1, 2019, 00:00

  • PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ALGERIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS20 RECENT ADVANCES IN THE EUROPEAN CROSS-BORDER COLLABORATIONS IN JOINT DRUG PROCUREMENT LANDSCAPE

    Nov 1, 2019, 00:00

  • PNS418 WHEN THE COMPARATOR HAS A CONFIDENTIAL PRICE - A REVIEW OF RECENT CASES IN SWEDEN

    Nov 1, 2019, 00:00

  • PRO132 DISEASE BURDEN OF X-LINKED HYPOPHOSPHATEMIA

    Nov 1, 2019, 00:00

  • PBI89 PHARMACOUTILIZATION OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED BY PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN AN ITALIAN REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • PMS78 CANADIAN REAL-WORLD EVIDENCE ON EPIDEMIOLOGY, OUTCOMES AND ECONOMICS OF MODERATE-TO-SEVERE OSTEOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN141 USE OF COST-EFFECTIVENESS AFFORDABILITY CURVES IN EVALUATING CANCER DRUGS IN ENGLAND

    Nov 1, 2019, 00:00

  • PMU87 REVIEW OF ORPHAN TREATMENTS ASSESSED BY NICE AND THE SMC IN THE UK.

    Nov 1, 2019, 00:00

  • PCN15 PROPHYLAXIS FOR BICALUTAMIDE-INDUCED GYNECOMASTIA: A NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PRS27 THE USE OF ECONOMICAL TRADITIONAL HERBAL MEDICINAL PLANTS AMONG DIFFERENT COMMUNITIES OF BALOCHISTAN AGAINST ASTHMA

    Nov 1, 2019, 00:00

  • PCV92 ANALYSING DATA OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO PROGRESSIVITY LEVELS IN HUNGARY (COMPARISON OF 2013 AND 2018)

    Nov 1, 2019, 00:00

  • PMU53 THE INCENTIVE FINANCIAL FRAMEWORK REGARDING FRENCH HOSPITAL PRESCRIPTION OF BIOSIMILAR MEDICINES WHEN DELIVERED IN RETAIL PHARMACY: IMPACT ANALYSIS OF ARTICLE 51 EXPERIMENTATION FOR 2018

    Nov 1, 2019, 00:00

  • PCN68 BRENTUXIMAB VEDOTIN FOR CONSOLIDATION THERAPY AFTER ASCT IN CD30+ HODGKIN'S LYMPHOMA: A SUSTAINABLE PHARMACEUTICAL EXPENDITURE FOR THE ITALIAN NATIONAL HEALTH SERVICE

    Nov 1, 2019, 00:00

  • PBI71 EXPLORING UNCERTAINTIES AND SOLUTIONS ALLOWING PATIENT ACCESS TO CAR T-CELL THERAPIES: LEARNING TODAY HOW TO IMPROVE TOMORROW

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PGI10 COST-UTILITY ANALYSIS OF USTEKINUMAB VS VEDOLIZUMAB IN CROHN DISEASE IN ITALY

    Nov 1, 2019, 00:00

  • PNS199 BARRIERS TO THE USE OF HEALTH SERVICES AMONG THE ELDERLY POPULATION OF A RURAL REGIONAL UNITY IN GREECE: A CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PRO120 EVOLUTION OF OBCS NECESSARY TO ACTIVATE VALUE WITHIN STEM CELL RARE DISEASES

    Nov 1, 2019, 00:00

  • PCN487 COST OF PROSTATE CANCER AND QUALITY OF LIFE IN EGYPT - A PATIENT PERSPECTIVE STUDY

    Nov 1, 2019, 00:00
  • «
  • 51 (current)
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »